|
1
|
Steiner PE and Higginson J:
Cholangiolocellular carcinoma of the liver. Cancer. 12:753–759.
1959. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hamilton SR and Aaltonen LA: Intrahepatic
cholangiocarcinoma. In: World Health Organization Classification of
TumorsPathology and Genetics of Tumours of the Digestive System.
IARC Press; Lyon: 2000
|
|
3
|
Theise ND, Nakashima O, Park YN and
Nakanuma Y: Combined hepatocellular-cholangiocarcinomaWorld Health
Organization Classification of Tumors. WHO classification of tumors
of the digestive system. Bosman FT, Carneiro F, Hruban RH and
Theise ND: IARC Press; Lyon: pp. 225–227. 2010
|
|
4
|
Liver Cancer Study Group of Japan, .
General rules for the clinical and pathological study of primary
liver cancer. 5th. Revised version. Tokyo, Kanehara: pp. 462009
|
|
5
|
Shiota K, Taguchi J, Nakashima O,
Nakashima M and Kojiro M: Clinicopathologic study on
cholangiolocellular carcinoma. Oncol Rep. 8:263–268.
2001.PubMed/NCBI
|
|
6
|
Ariizumi S, Kotera Y, Katagiri S, Nakano
M, Nakanuma Y, Saito A and Yamamoto M: Long-term survival of
patients with cholangiolocellular carcinoma after curative
hepatectomy. Ann Surg Oncol. 21:(Suppl 3). S451–S458. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Miura K, Shirasaka T, Yamaue H and Sasaki
I: S-1 as a core anticancer fluoropyrimidine agent. Expert Opin
Drug Deliv. 9:273–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Furuse J, Okusaka T, Boku N, Ohkawa S,
Sawaki A, Masumoto T and Funakoshi A: S-1 monotherapy as first-line
treatment in patients with advanced biliary tract cancer: A
multicenter phase II study. Cancer Chemother Pharmacol. 62:849–855.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sakata Y, Ohtsu A, Horikoshi N, Sugimachi
K, Mitachi Y and Taguchi T: Late phase II study of novel oral
fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1
M otastat potassium) in advanced gastric cancer patients. Eur J
Cancer. 34:1715–1720. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ohtsu A, Baba H, Sakata Y, Mitachi Y,
Horikoshi N, Sugimachi K and Taguchi T: Phase II study of S-1, a
novel oral fluorophyrimidine derivative, in patients with
metastatic colorectal carcinoma. S-1 Cooperative Colorectal
Carcinoma Study Group. Br J Cancer. 83:141–145. 2000.PubMed/NCBI
|
|
11
|
Kawahara M, Furuse K, Segawa Y, Yoshimori
K, Matsui K, Kudoh S, Hasegawa K and Niitani H: S-1 Cooperative
Study Group (Lung Cancer Working Group): Phase II study of S-1, a
novel oral fluorouracil, in advanced non-small-cell lung cancer. Br
J Cancer. 85:939–943. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saeki T, Takashima S, Sano M, Horikoshi N,
Miura S, Shimizu S, Morimoto K, Kimura M and Taguchi T: A late
phase II clinical study of S-1 in patients with progressed,
refractory breast cancer. Cancer & chemotherapy. 31:539–547.
2004.(In Japanese).
|
|
13
|
Nakano M: Histopathological characteristic
of cholangiolocellular carcinoma. J Biliary Tract Pancreas.
25:343–349. 2004.
|
|
14
|
Vogl TJ, Schwarz W, Eichler K, Hochmuth K,
Hammerstingl R, Jacob U, Scheller A, Zangos S and Heller M: Hepatic
intraarterial chemotherapy with gemcitabine in patients with
unresectable cholangiocarcinomas and liver metastases of pancreatic
cancer: A clinical study on maximum tolerable dose and treatment
efficacy. J Cancer Res Clin Oncol. 132:745–755. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park I, Lee JL, Ryu MH, Kim TW, Lee S
Sook, Park D Hyun, Soo Lee S, Wan Seo D, Koo Lee S and Kim MH:
Prognostic factors and predictive model in patients with advanced
biliary tract adenocarcinoma receiving first-line palliative
chemotherapy. Cancer. 115:4148–4155. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matsuda M, Hara M, Suzuki T, Kono H and
Fujii H: Synchronously resected double primary hepatic cancers -
hepatocellular carcinoma and cholangiolocellular carcinoma. J
Hepatobiliary Pancreat Surg. 13:571–576. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kanamoto M, Yoshizumi T, Ikegami T, Imura
S, Morine Y, Ikemoto T, Sano N and Shimada M: Cholangiolocellular
carcinoma containing hepatocellular carcinoma and cholangiocellular
carcinoma, extremely rare tumor of the liver: A case report. J Med
Invest. 55:161–165. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lacomis JM, Baron RL, Oliver JH III,
Nalesnik MA and Federle MP: Cholangiocarcinoma: Delayed CT contrast
enhancement patterns. Radiology. 203:98–104. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Komuta M, Spee B, Borght S Vander, De Vos
R, Verslype C, Aerts R, Yano H, Suzuki T, Matsuda M, Fujii H, et
al: Clinicopathological study on cholangiolocellular carcinoma
suggesting hepatic progenitor cell origin. Hepatology.
47:1544–1556. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maeno S, Kondo F, Sano K, Takada T and
Asano T: Morphometric and immunohistochemical study of
cholangiolocellular carcinoma: Comparison with non-neoplastic
cholangiole, interlobular duct and septal duct. J Hepatobiliary
Pancreat Sci. 19:289–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kondo F and Fukusato T: Pathogenesis of
cholangiolocellular carcinoma: Possibility of an interlobular duct
origin. Intern Med. 54:1685–1694. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Joshita S, Ichijo T, Suzuki F, Yokoyama T,
Sugiyama Y, Fukushima M, Kamijo A, Komatsu M, Umemura T, Yoshizawa
K, et al: A case of well-differentiated cholangiolocellular
carcinoma visualized with contrast-enhanced ultrasonography using
Sonazoid. Hepatol Res. 39:207–212. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maeda T, Hashimoto K, Ishida T, Yamashita
Y, Saeki H, Kawanaka H, Uchiyama H, Ikeda T, Tsujitani S and
Maehara Y: Repeat hepatectomy for intrahepatic recurrence of
cholangiolocellular carcinoma. Fukuoka Acta Medica. 104:564–568.
2013.
|
|
26
|
Motosugi U, Ichikawa T, Nakajima H, Araki
T, Matsuda M, Suzuki T, Fujii H, Nakazawa T and Yamaguchi H:
Cholangiolocellular carcinoma of the liver: Imaging findings. J
Comput Assist Tomogr. 33:682–688. 2009. View Article : Google Scholar : PubMed/NCBI
|
